Ravindra Kumar
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Ravindra Kumar has a total of 96 co-authors. Here are the top co-authors by number of shared publications:
- Manish Kumar
Department of Biophysics, University of Delhi South Campus, New Delhi, India
15 shared publications Bandana Kumari
RNA Biology Laboratory, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Frederick, MD, United States
14 shared publicationsAbhishikha Srivastava
Department of Biophysics, University of Delhi South Campus, New Delhi 110021, India
3 shared publications- Aleksandra Beric
Department of Psychiatry, Washington University in Saint Louis School of Medicine, St. Louis, MO 63110, USA
3 shared publications Anjali Garg
University of Delhi South Campus, New Delhi, India
3 shared publications- Laura Ibanez
Department of Psychiatry, Washington University School of Medicine, St. Louis, MO 63110, USA
3 shared publications
Latest Publications
- Open Access
- 29 May 2026
- Published by Springer Nature in Nature Communications
- Vol. 17 (1)
ToxiTaRGET: a multi-omics database for toxicant-responsive molecular targets
Environmental toxicant exposures can induce widespread alterations in both the transcriptome and epigenome of mammals, and directly contribute to the increased risk of various diseases, including cardiovascular disorders, cancer, and neurological disorders. To evaluate how early-life toxicants produce long-term impacts on the transcriptome and epigenome in mice, the Toxicant Exposures and Responses by Genomic and Epigenomic Regulators of Transcription II (TaRGET II) Consortium generated a landmark resource comprising 3607 multi-omics datasets from longitudinal studies in mice. The molecular changes in responding to distinct environmental toxicants, including arsenic (As), lead (Pb), bisphenol A (BPA), tributyltin (TBT), di-2-ethylhexyl phthalate (DEHP), dioxin (TCDD), and fine particulate matter (PM2.5), were systematically identified and visualized on an integrative platform, ToxiTaRGET, to allow quickly search and browse by researchers. ToxiTaRGET houses a rich repository of molecular signatures, including gene expression, chromatin accessibility, and DNA methylation profiles, in response to early-life toxicant exposures. These molecular signatures span multiple biologically important tissues in both male and female mice at three distinct life stages, offering a valuable resource for the environmental health and toxicogenomic research communities.
- 29 May 2026
- Published by Springer Nature in Nature Communications
- Vol. 17 (1)
Open AccessToxiTaRGET: a multi-omics database for toxicant-responsive molecular targets
Environmental toxicant exposures can induce widespread alterations in both the transcriptome and epigenome of mammals, and directly contribute to the increased risk of various diseases, including cardiovascular disorders, cancer, and neurological disorders. To evaluate how early-life toxicants produce long-term impacts on the transcriptome and epigenome in mice, the Toxicant Exposures and Responses by Genomic and Epigenomic Regulators of Transcription II (TaRGET II) Consortium generated a landmark resource comprising 3607 multi-omics datasets from longitudinal studies in mice. The molecular changes in responding to distinct environmental toxicants, including arsenic (As), lead (Pb), bisphenol A (BPA), tributyltin (TBT), di-2-ethylhexyl phthalate (DEHP), dioxin (TCDD), and fine particulate matter (PM2.5), were systematically identified and visualized on an integrative platform, ToxiTaRGET, to allow quickly search and browse by researchers. ToxiTaRGET houses a rich repository of molecular signatures, including gene expression, chromatin accessibility, and DNA methylation profiles, in response to early-life toxicant exposures. These molecular signatures span multiple biologically important tissues in both male and female mice at three distinct life stages, offering a valuable resource for the environmental health and toxicogenomic research communities.
- Open Access
- 12 January 2026
- Published by Frontiers Media SA in Frontiers in Molecular Neuroscience
- Vol. 18, 1767630
Editorial: Advancing therapeutics for Alzheimer's disease and related dementias through multi-omics data analysis in ethnically diverse populations
Alzheimer's disease (AD) is a neurodegenerative disorder characterized by progressive cognitive decline and the accumulation of extracellular amyloid-beta (Aβ) plaques and intracellular neurofibrillary tangles in the brain tissue. Like other dementias, AD disproportionately affects certain racial and ethnic groups, remaining a major global health challenge that demands improved strategies for early detection, mechanistic understanding, and therapeutic intervention. This special issue focuses on studies investigating microglia dysfunction in various neurological disorders, including AD, while considering factors like experimental models, sex, age, and ethnicity. These studies leverage advanced computational methods to integrate and analyze molecular data. Such approaches, including multi-omics analyses (shown in Figure 1), are elucidating AD's molecular landscape and enabling personalized strategies for neurodegenerative diseases, such as developing genetic and molecular biomarkers, identifying novel therapeutic targets, and designing more effective clinical trials. Ultimately, this research is essential for advancing our understanding of microglial function and dysfunction across diverse populations. In this special issue, we included six articles, including two reviews and four research articles, discussed briefly below. Two studies focus on the marker identification, highlighting potential for improved diagnosis and therapeutic targeting in AD. Li Wu et.al demonstrate that bloodderived cell-free RNA (cfRNA) can serve as a non-invasive biomarker for detecting molecular changes associated with AD. By integrating cfRNA profiles with single-cell transcriptomic (scRNA) and machine learning (ML) approaches, the authors identified a panel of 34 signature genes, achieving robust diagnostic performance (~90% AUC). These findings underscore the potential of these signature genes for early, non-invasive AD detection and patient stratification.Xuan Xu et al. demonstrate how mitochondrial dysfunction serves as a unifying yet divergent element in the pathobiology of AD and glioblastoma (GBM). Single-cell analyses uncovered distinct cell type signatures, with LPAR1, regulating mitochondrial dynamics and inflammation in AD, and promoted invasion and altered bioenergetics in GBM. Further machine learning integration identified four key genes namely, EFHD1, SASH1, FAM110B, and SLC25A18 as central mitochondrial regulators. These markers show potential for improved diagnosis and therapeutic targeting although experimental validation and larger cohorts are needed to confirm their clinical relevance. Overall, single-cell deep profiling reveals key regulatory biomarkers and pathways that could improve early diagnosis and therapeutic targeting. Zhang et al. analyzed the relationship between atorvastatin and memory function by integrating data from the National Health and Nutrition Examination Survey (NHANES) and the Food and Drug Administration Adverse Event Reporting System (FAERS). Atorvastatin, a statin drug approved in 2003, is primarily proposed for treating hypercholesterolemia and preventing cardiovascular disease. NHANES findings suggested a potential protective effect of atorvastatin against memory decline while FAERS data revealed specific cognitive adverse events associated with atorvastatin use. Consequently, clinicians and patients should consider atorvastatin's potential benefits against its potential cognitive risks, accounting for individual patient variability, drug responsiveness and lifestyle factors, and implementing appropriate monitoring protocols. Also, three articles described the early screening and physical therapy-based method to improve quality of life in AD patients. Cagla Elikucuk et al. highlighted that bedside and instrumental swallowing assessments are effective for early detection of dysphagia, especially in older adults. In ICU patients, however, dysphagia is often overlooked due to cognitive and behavioral issues. Aspiration pneumonia remains a leading cause of death in this group. The authors noted that early screening and exercise-based swallowing therapy can reduce complications. They also emphasized the importance of diet modification and caregiver education as preventive strategies. Swallowing therapy may shorten hospital stays and improve outcomes while PEG tubes show no clear benefit for survival or quality of life. Malnutrition and poor functional status worsen quality of life, highlighting the need for better-designed studies on dysphagia and nutrition interventions. Wu et al. compared the effectiveness of five physiotherapy interventions in the context of AD network meta-analysis. They found that game therapy and acupuncture therapy improved mental well-being and the ability to perform daily activities, with acupuncture producing particularly notable gains in cognitive performance. In addition, music therapy and exercise therapy also contribute cognitive benefits and improvement in function outcomes, respectively. Wu et al.'s analysis demonstrated the significance of personalized physiotherapy and psychotherapeutic approaches in AD care. They also illustrated some of the therapeutic effects that were cognitive, including neuroplasticity and increased blood flow, and the reduction of amyloid protein. Overall, their findings support the use of individualized physiotherapy treatment programs to improve quality of life in AD patients. Adak et al. conducted an extensive review of AD screening models focused on early identification of at-risk individuals before clinical symptoms appear. The review encompasses a broad spectrum of in vivo and in vitro models, including pharmacologically induced and transgenic animal models, as well as neuronal cell cultures models. These models are essential for studying key AD pathophysiological mechanisms such as tau pathology, Aβ aggregation, synaptic dysfunction, and neuroinflammation. In vivo models involve behavioral...
- 12 January 2026
- Published by Frontiers Media SA in Frontiers in Molecular Neuroscience
- Vol. 18, 1767630
Open AccessEditorial: Advancing therapeutics for Alzheimer's disease and related dementias through multi-omics data analysis in ethnically diverse populations
Alzheimer's disease (AD) is a neurodegenerative disorder characterized by progressive cognitive decline and the accumulation of extracellular amyloid-beta (Aβ) plaques and intracellular neurofibrillary tangles in the brain tissue. Like other dementias, AD disproportionately affects certain racial and ethnic groups, remaining a major global health challenge that demands improved strategies for early detection, mechanistic understanding, and therapeutic intervention. This special issue focuses on studies investigating microglia dysfunction in various neurological disorders, including AD, while considering factors like experimental models, sex, age, and ethnicity. These studies leverage advanced computational methods to integrate and analyze molecular data. Such approaches, including multi-omics analyses (shown in Figure 1), are elucidating AD's molecular landscape and enabling personalized strategies for neurodegenerative diseases, such as developing genetic and molecular biomarkers, identifying novel therapeutic targets, and designing more effective clinical trials. Ultimately, this research is essential for advancing our understanding of microglial function and dysfunction across diverse populations. In this special issue, we included six articles, including two reviews and four research articles, discussed briefly below. Two studies focus on the marker identification, highlighting potential for improved diagnosis and therapeutic targeting in AD. Li Wu et.al demonstrate that bloodderived cell-free RNA (cfRNA) can serve as a non-invasive biomarker for detecting molecular changes associated with AD. By integrating cfRNA profiles with single-cell transcriptomic (scRNA) and machine learning (ML) approaches, the authors identified a panel of 34 signature genes, achieving robust diagnostic performance (~90% AUC). These findings underscore the potential of these signature genes for early, non-invasive AD detection and patient stratification.Xuan Xu et al. demonstrate how mitochondrial dysfunction serves as a unifying yet divergent element in the pathobiology of AD and glioblastoma (GBM). Single-cell analyses uncovered distinct cell type signatures, with LPAR1, regulating mitochondrial dynamics and inflammation in AD, and promoted invasion and altered bioenergetics in GBM. Further machine learning integration identified four key genes namely, EFHD1, SASH1, FAM110B, and SLC25A18 as central mitochondrial regulators. These markers show potential for improved diagnosis and therapeutic targeting although experimental validation and larger cohorts are needed to confirm their clinical relevance. Overall, single-cell deep profiling reveals key regulatory biomarkers and pathways that could improve early diagnosis and therapeutic targeting. Zhang et al. analyzed the relationship between atorvastatin and memory function by integrating data from the National Health and Nutrition Examination Survey (NHANES) and the Food and Drug Administration Adverse Event Reporting System (FAERS). Atorvastatin, a statin drug approved in 2003, is primarily proposed for treating hypercholesterolemia and preventing cardiovascular disease. NHANES findings suggested a potential protective effect of atorvastatin against memory decline while FAERS data revealed specific cognitive adverse events associated with atorvastatin use. Consequently, clinicians and patients should consider atorvastatin's potential benefits against its potential cognitive risks, accounting for individual patient variability, drug responsiveness and lifestyle factors, and implementing appropriate monitoring protocols. Also, three articles described the early screening and physical therapy-based method to improve quality of life in AD patients. Cagla Elikucuk et al. highlighted that bedside and instrumental swallowing assessments are effective for early detection of dysphagia, especially in older adults. In ICU patients, however, dysphagia is often overlooked due to cognitive and behavioral issues. Aspiration pneumonia remains a leading cause of death in this group. The authors noted that early screening and exercise-based swallowing therapy can reduce complications. They also emphasized the importance of diet modification and caregiver education as preventive strategies. Swallowing therapy may shorten hospital stays and improve outcomes while PEG tubes show no clear benefit for survival or quality of life. Malnutrition and poor functional status worsen quality of life, highlighting the need for better-designed studies on dysphagia and nutrition interventions. Wu et al. compared the effectiveness of five physiotherapy interventions in the context of AD network meta-analysis. They found that game therapy and acupuncture therapy improved mental well-being and the ability to perform daily activities, with acupuncture producing particularly notable gains in cognitive performance. In addition, music therapy and exercise therapy also contribute cognitive benefits and improvement in function outcomes, respectively. Wu et al.'s analysis demonstrated the significance of personalized physiotherapy and psychotherapeutic approaches in AD care. They also illustrated some of the therapeutic effects that were cognitive, including neuroplasticity and increased blood flow, and the reduction of amyloid protein. Overall, their findings support the use of individualized physiotherapy treatment programs to improve quality of life in AD patients. Adak et al. conducted an extensive review of AD screening models focused on early identification of at-risk individuals before clinical symptoms appear. The review encompasses a broad spectrum of in vivo and in vitro models, including pharmacologically induced and transgenic animal models, as well as neuronal cell cultures models. These models are essential for studying key AD pathophysiological mechanisms such as tau pathology, Aβ aggregation, synaptic dysfunction, and neuroinflammation. In vivo models involve behavioral...
- Open Access
Orthogonal validation of PD Biomarkers: Multi-platform proteomics profiling of CSF, Plasma, and Urine confirms DDC as a consistent candidate
Background: High throughput proteomics has enabled hypothesis free biomarker discovery. However, differences in sample sizes, biological fluid, and quantification technologies have limited replication and validation of the results, and studies on the cross-platform variability are lacking. Here, we present the first orthogonal validation across three platforms in Parkinson’s disease (PD) to understand the technical and biological challenges of proteomic studies. Methods: We have leveraged publicly available proteomic data from cerebrospinal fluid (CSF), plasma, and urine within the Parkinson’s Progression Markers Initiative (PPMI) cohort, generated using SomaScan5K (CSF), mass spectrometry (MS; CSF, plasma, and urine), and Olink Explore (CSF and plasma). Across platforms, we compared 375 proteins that were consistently quantified. We performed differential abundance analysis comparing PD versus healthy controls followed by sensitivity analyses (mutation carriers, at-risk participants, longitudinal analyses) to further understand the findings. Results: In CSF, we found significant correlations between effect sizes from the 375 proteins quantified by SomaScan5K and MS (ρ=0.42, p=2.60×10 □ □), as well as SomaScan5K and Olink Explore (ρ=0.15, p=3.15×10□ 3 ) while MS and Olink Explore showed no significant correlations in CSF or plasma. Orthogonal validation identified two proteins (DLK1, GSTA3) replicated between SomaScan5K and Olink Explore and seven proteins (ALCAM, CHL1, CNDP1, NCAM2, PEBP1, PTPRS, SCG2) replicated between MS and SomaScan5K. No proteins replicated between MS and Olink Explore in CSF or plasma. DDC showed consistent dysregulation across analyses. In CSF (Olink Explore), it was dysregulated in PD participants (beta=0.79, p=8.49×10 −16 ), and in at-risk individuals (beta=0.64, p=1.41×10 −7 ) including those with hyposmia (beta=0.70, p=2.13×10 −5 ) and REM Sleep Behavior Disorder (beta=0.52, p=1.00×10 −3 ). In urine, DDC was higher in at-risk individuals (beta=0.43, p=7.28×10 −5 ), driven by LRRK2 + at-risk participants (beta=0.59, p=1.74×10 −6 ), as well as in symptomatic mutation carriers, LRRK2 + (beta=0.68, p=9.08×10 −8 ), and GBA + (beta=0.28, p=0.04). Conclusions: Biologically, these findings add further evidence that DDC has strong potential as a biomarker. Methodologically, our findings emphasize that platform selection can introduce more variance than that originating from disease status, which limits the reproducibility across technologies. This highlights the challenges and importance of cross-platform validation in proteomic biomarker research, and the translation of those discoveries to the clinic.
Open AccessOrthogonal validation of PD Biomarkers: Multi-platform proteomics profiling of CSF, Plasma, and Urine confirms DDC as a consistent candidate
Background: High throughput proteomics has enabled hypothesis free biomarker discovery. However, differences in sample sizes, biological fluid, and quantification technologies have limited replication and validation of the results, and studies on the cross-platform variability are lacking. Here, we present the first orthogonal validation across three platforms in Parkinson’s disease (PD) to understand the technical and biological challenges of proteomic studies. Methods: We have leveraged publicly available proteomic data from cerebrospinal fluid (CSF), plasma, and urine within the Parkinson’s Progression Markers Initiative (PPMI) cohort, generated using SomaScan5K (CSF), mass spectrometry (MS; CSF, plasma, and urine), and Olink Explore (CSF and plasma). Across platforms, we compared 375 proteins that were consistently quantified. We performed differential abundance analysis comparing PD versus healthy controls followed by sensitivity analyses (mutation carriers, at-risk participants, longitudinal analyses) to further understand the findings. Results: In CSF, we found significant correlations between effect sizes from the 375 proteins quantified by SomaScan5K and MS (ρ=0.42, p=2.60×10 □ □), as well as SomaScan5K and Olink Explore (ρ=0.15, p=3.15×10□ 3 ) while MS and Olink Explore showed no significant correlations in CSF or plasma. Orthogonal validation identified two proteins (DLK1, GSTA3) replicated between SomaScan5K and Olink Explore and seven proteins (ALCAM, CHL1, CNDP1, NCAM2, PEBP1, PTPRS, SCG2) replicated between MS and SomaScan5K. No proteins replicated between MS and Olink Explore in CSF or plasma. DDC showed consistent dysregulation across analyses. In CSF (Olink Explore), it was dysregulated in PD participants (beta=0.79, p=8.49×10 −16 ), and in at-risk individuals (beta=0.64, p=1.41×10 −7 ) including those with hyposmia (beta=0.70, p=2.13×10 −5 ) and REM Sleep Behavior Disorder (beta=0.52, p=1.00×10 −3 ). In urine, DDC was higher in at-risk individuals (beta=0.43, p=7.28×10 −5 ), driven by LRRK2 + at-risk participants (beta=0.59, p=1.74×10 −6 ), as well as in symptomatic mutation carriers, LRRK2 + (beta=0.68, p=9.08×10 −8 ), and GBA + (beta=0.28, p=0.04). Conclusions: Biologically, these findings add further evidence that DDC has strong potential as a biomarker. Methodologically, our findings emphasize that platform selection can introduce more variance than that originating from disease status, which limits the reproducibility across technologies. This highlights the challenges and importance of cross-platform validation in proteomic biomarker research, and the translation of those discoveries to the clinic.
- Open Access
- 20 August 2025
- Published by Springer Nature in Research Square
Toxicogenomic Insights into Environmental Toxicant Exposures: The TaRGET II Resource
Environmental exposures to toxic chemicals can profoundly alter the transcriptome and epigenome in both humans and animals, contributing to disease development across the lifespan. To elucidate how early-life exposure to toxicants exerts such persistent effects, the Toxicant Exposures and Responses by Genomic and Epigenomic Regulators of Transcription II (TaRGET II) Consortium generated a landmark resource comprising 2,570 epigenomes and 1,043 transcriptomes from longitudinal studies in mice. All data are publicly available through the TaRGET II data portal and the WashU Epigenome Browser. This resource from target (liver, brain, lung, heart) and surrogate (blood) tissues at weaning (3 weeks) and two adult time-points (5 and 10 months) characterized the molecular response to arsenic (As), lead (Pb), bisphenol-A (BPA), di-2-ethylhexyl phthalate(DEHP), tributyltin (TBT), tetrachlorodibenzo-p-dioxin (TCDD), and particulate matter with a diameter of <2.5μm (PM2.5). The findings revealed persistent, toxicant-specific, sex-dependent epigenomic and transcriptomic perturbations, resulting in disrupted expression of 14,908 genes, altered chromatin accessibility at 87,409 regulatory elements, DNA methylation changes at 113,186 genomic regions, and chromatin state switching of histone modifications. The resulting high-resolution map of how environmental exposures reprogram the epigenome and transcriptome is broadly accessible via ToxiTaRGET database, offering unparalleled opportunities for the scientific community to investigate the molecular underpinnings of environmental toxicant exposures and their contributions to disease pathogenesis.
- 20 August 2025
- Published by Springer Nature in Research Square
Open AccessToxicogenomic Insights into Environmental Toxicant Exposures: The TaRGET II Resource
Environmental exposures to toxic chemicals can profoundly alter the transcriptome and epigenome in both humans and animals, contributing to disease development across the lifespan. To elucidate how early-life exposure to toxicants exerts such persistent effects, the Toxicant Exposures and Responses by Genomic and Epigenomic Regulators of Transcription II (TaRGET II) Consortium generated a landmark resource comprising 2,570 epigenomes and 1,043 transcriptomes from longitudinal studies in mice. All data are publicly available through the TaRGET II data portal and the WashU Epigenome Browser. This resource from target (liver, brain, lung, heart) and surrogate (blood) tissues at weaning (3 weeks) and two adult time-points (5 and 10 months) characterized the molecular response to arsenic (As), lead (Pb), bisphenol-A (BPA), di-2-ethylhexyl phthalate(DEHP), tributyltin (TBT), tetrachlorodibenzo-p-dioxin (TCDD), and particulate matter with a diameter of <2.5μm (PM2.5). The findings revealed persistent, toxicant-specific, sex-dependent epigenomic and transcriptomic perturbations, resulting in disrupted expression of 14,908 genes, altered chromatin accessibility at 87,409 regulatory elements, DNA methylation changes at 113,186 genomic regions, and chromatin state switching of histone modifications. The resulting high-resolution map of how environmental exposures reprogram the epigenome and transcriptome is broadly accessible via ToxiTaRGET database, offering unparalleled opportunities for the scientific community to investigate the molecular underpinnings of environmental toxicant exposures and their contributions to disease pathogenesis.
- Open Access
A Comprehensive Study of Circulating Blood Linear RNA nominates CD55 and DLD as novel causal genes and early-stage biomarkers for Parkinson’s Disease
We leveraged transcriptomic data from 4,343 participants from four independent datasets to robustly identify and annotate circulating PD-associated transcripts. We identified 296 differentially expressed transcripts, 28 of which were transcribed from known PD-associated loci. Further, we found a significant overlap between our findings and transcripts dysregulated in brain, as well as proteins differentially accumulated in CSF. Expression of the identified transcripts was affected by genetic background including ancestry and PD-related mutations, and nearly half of the identified transcripts were dysregulated before symptom onset. The differentially expressed transcripts were utilized to develop three predictive models that distinguished between PD and healthy controls with a ROC AUC of 0.727-0.733. The predictive models were capable of detecting PD transcriptomic signatures even before symptom onset. One transcript, DLD, showed particular promise as an early stage, minimally invasive PD biomarker that was differentially expressed in whole blood, brain and CSF. This transcript significantly related to PD in the eQTL analyses and in two of the three predictive models.
Open AccessA Comprehensive Study of Circulating Blood Linear RNA nominates CD55 and DLD as novel causal genes and early-stage biomarkers for Parkinson’s Disease
We leveraged transcriptomic data from 4,343 participants from four independent datasets to robustly identify and annotate circulating PD-associated transcripts. We identified 296 differentially expressed transcripts, 28 of which were transcribed from known PD-associated loci. Further, we found a significant overlap between our findings and transcripts dysregulated in brain, as well as proteins differentially accumulated in CSF. Expression of the identified transcripts was affected by genetic background including ancestry and PD-related mutations, and nearly half of the identified transcripts were dysregulated before symptom onset. The differentially expressed transcripts were utilized to develop three predictive models that distinguished between PD and healthy controls with a ROC AUC of 0.727-0.733. The predictive models were capable of detecting PD transcriptomic signatures even before symptom onset. One transcript, DLD, showed particular promise as an early stage, minimally invasive PD biomarker that was differentially expressed in whole blood, brain and CSF. This transcript significantly related to PD in the eQTL analyses and in two of the three predictive models.
- Open Access
- 27 November 2024
- Published by Academia.edu in Academia Biology
- Vol. 2 (4)
Unlocking biological complexity: the role of machine learning in integrative multi-omics
The increasing complexity of biological systems demands advanced analytical approaches to decode the underlying mechanisms of health and disease. Integrative multi-omics approaches use multi-layered datasets such as genomic, transcriptomic, proteomic, and metabolomic data to understand biological processes much more comprehensively compared to the single-omics analysis and to provide a comprehensive view of cellular and molecular processes. However, these integrative approaches have their own computational and analytical challenges due to the large volume and nature of multi-omics data. Machine learning has emerged as a powerful tool to help and resolve these challenges. It offers sophisticated algorithms that can identify and discover hidden patterns and provide insights into complex biological networks. By integrating machine learning in multi-omics, we can enhance our understanding of drug discovery, disease, pathway, and network analysis. Machine learning and ensemble methods allow researchers to model nonlinear relationships and manage high-dimensional data, improving the precision of predictions. This approach paves the way for personalized medicine by identifying unique molecular signatures for individual patients, which can provide valuable insights into treatment planning and support more effective treatment. As machine learning continues to evolve, its role in multi-omics analysis will be pivotal in advancing our ability to interpret biological complexity and translate findings into clinical applications.
- 27 November 2024
- Published by Academia.edu in Academia Biology
- Vol. 2 (4)
Open AccessUnlocking biological complexity: the role of machine learning in integrative multi-omics
The increasing complexity of biological systems demands advanced analytical approaches to decode the underlying mechanisms of health and disease. Integrative multi-omics approaches use multi-layered datasets such as genomic, transcriptomic, proteomic, and metabolomic data to understand biological processes much more comprehensively compared to the single-omics analysis and to provide a comprehensive view of cellular and molecular processes. However, these integrative approaches have their own computational and analytical challenges due to the large volume and nature of multi-omics data. Machine learning has emerged as a powerful tool to help and resolve these challenges. It offers sophisticated algorithms that can identify and discover hidden patterns and provide insights into complex biological networks. By integrating machine learning in multi-omics, we can enhance our understanding of drug discovery, disease, pathway, and network analysis. Machine learning and ensemble methods allow researchers to model nonlinear relationships and manage high-dimensional data, improving the precision of predictions. This approach paves the way for personalized medicine by identifying unique molecular signatures for individual patients, which can provide valuable insights into treatment planning and support more effective treatment. As machine learning continues to evolve, its role in multi-omics analysis will be pivotal in advancing our ability to interpret biological complexity and translate findings into clinical applications.
- Open Access
Plasma acellular transcriptome contains Parkinson’s disease signatures that can inform clinical diagnosis
We aimed to identify plasma cell-free transcripts (cfRNA) associated with Parkinson’s disease (PD) that also have a high predictive value to differentiate PD from healthy controls. Leveraging two independent populations from two different movement disorder centers we identified 2,188 differentially expressed cfRNAs after meta-analysis. The identified transcripts were enriched in PD relevant pathways, such as PD (p=9.26×10 -4 ), ubiquitin-mediated proteolysis (p=7.41×10 -5 ) and endocytosis (p=4.21×10 -6 ). Utilizing in-house and publicly available brain, whole blood, and acellular plasma transcriptomic and proteomic PD datasets, we found significant overlap across dysregulated biological species in the different tissues and the different biological layers. We developed three predictive models containing increasing number of transcripts that can distinguish PD from healthy control with an area under the ROC Curve (AUC) ≥0.85. Finally, we showed that several of the predictive transcripts significantly correlate with symptom severity measured by UPDRS-III. Overall, we have demonstrated that cfRNA contains pathological signatures and has the potential to be utilized as biomarker to aid in PD diagnostics and monitoring.
Open AccessPlasma acellular transcriptome contains Parkinson’s disease signatures that can inform clinical diagnosis
We aimed to identify plasma cell-free transcripts (cfRNA) associated with Parkinson’s disease (PD) that also have a high predictive value to differentiate PD from healthy controls. Leveraging two independent populations from two different movement disorder centers we identified 2,188 differentially expressed cfRNAs after meta-analysis. The identified transcripts were enriched in PD relevant pathways, such as PD (p=9.26×10 -4 ), ubiquitin-mediated proteolysis (p=7.41×10 -5 ) and endocytosis (p=4.21×10 -6 ). Utilizing in-house and publicly available brain, whole blood, and acellular plasma transcriptomic and proteomic PD datasets, we found significant overlap across dysregulated biological species in the different tissues and the different biological layers. We developed three predictive models containing increasing number of transcripts that can distinguish PD from healthy control with an area under the ROC Curve (AUC) ≥0.85. Finally, we showed that several of the predictive transcripts significantly correlate with symptom severity measured by UPDRS-III. Overall, we have demonstrated that cfRNA contains pathological signatures and has the potential to be utilized as biomarker to aid in PD diagnostics and monitoring.
- 13 October 2021
- Published by Institute of Electrical and Electronics Engineers (IEEE)
- p. 1-9
Identification of chloroplast and sub-chloroplast proteins from sequence-attributed features using support vector machine and domain information
Chloroplasts are one of the most important organelles of plants including algae. A number of vital biological pathways in them are exclusively confined to the chloroplast, thus, indicating the significance of chloroplastidic proteins. Hence, prediction of chloroplastidic proteins and their localization within the chloroplast (sub-chloroplastidial localization) can be of paramount importance in understanding the role of both novel and known chloroplastidic proteins. Several experimental methods have been developed to determine the subcellular localization of proteins; however, annotation of every protein using the experimental methods requires a lot of time and resources. To overcome these shortcomings of experimental approaches many computational methods have been proposed which minimize the amount of time and resources required. In pursuit of speeding up the prediction of chloroplastidic proteins and their sub-chloroplastidial localization besides maintaining efficiency, we developed Pfam domain and support vector machine based two level prediction frameworks, namely, SubChloroPred. At first level, SubChloroPred predicts the chloroplastidic proteins and at second level, their localization at sub-chloroplastidic locations such as thylakoid and stroma would be predicted. SubChloroPred has overall prediction accuracy of 94.86% at the first level and accuracies of 75.91% and 74.26% at the second level in thylakoid and stroma respectively. We have also developed a freely accessible webserver as well as standalone software for the use of scientific community, which can be accessed from the link http://proteininformatics.org/mkumar/SubChloroPred.
- 13 October 2021
- Published by Institute of Electrical and Electronics Engineers (IEEE)
- p. 1-9
Identification of chloroplast and sub-chloroplast proteins from sequence-attributed features using support vector machine and domain information
Chloroplasts are one of the most important organelles of plants including algae. A number of vital biological pathways in them are exclusively confined to the chloroplast, thus, indicating the significance of chloroplastidic proteins. Hence, prediction of chloroplastidic proteins and their localization within the chloroplast (sub-chloroplastidial localization) can be of paramount importance in understanding the role of both novel and known chloroplastidic proteins. Several experimental methods have been developed to determine the subcellular localization of proteins; however, annotation of every protein using the experimental methods requires a lot of time and resources. To overcome these shortcomings of experimental approaches many computational methods have been proposed which minimize the amount of time and resources required. In pursuit of speeding up the prediction of chloroplastidic proteins and their sub-chloroplastidial localization besides maintaining efficiency, we developed Pfam domain and support vector machine based two level prediction frameworks, namely, SubChloroPred. At first level, SubChloroPred predicts the chloroplastidic proteins and at second level, their localization at sub-chloroplastidic locations such as thylakoid and stroma would be predicted. SubChloroPred has overall prediction accuracy of 94.86% at the first level and accuracies of 75.91% and 74.26% at the second level in thylakoid and stroma respectively. We have also developed a freely accessible webserver as well as standalone software for the use of scientific community, which can be accessed from the link http://proteininformatics.org/mkumar/SubChloroPred.
- Open Access
- 27 August 2021
- Published by Oxford University Press (OUP) in Bioinformatics
- Vol. 38 (2) , 570-572
TPWshiny: an interactive R/Shiny app to explore cell line transcriptional responses to anti-cancer drugs
Summary: The NCI Transcriptional Pharmacodynamics Workbench (NCI TPW) is an extensive compilation of directly measured transcriptional responses to anti-cancer agents across the well-characterized NCI-60 cancer cell lines. The NCI TPW data are publicly available through a web interface that allows limited user interaction with the data. We developed ‘TPWshiny’ as a standalone, easy to install, R application to facilitate more interactive data exploration.With no programming skills required, TPWshiny provides an intuitive and comprehensive graphical interface to help researchers understand the response of tumor cell lines to 15 therapeutic agents. The data are presented in interactive scatter plots, heatmaps, time series and Venn diagrams. Data can be queried by drug concentration, time point, gene and tissue type. Researchers can download the data for further analysis.Availability and implementation: Users can download the ready-to-use, self-extracting package for Windows or macOS, and R source code from the project website (https://brb.nci.nih.gov/TPWshiny/). TPWshiny documentation and additional information can be found on the project website.
- 27 August 2021
- Published by Oxford University Press (OUP) in Bioinformatics
- Vol. 38 (2) , 570-572
Open AccessTPWshiny: an interactive R/Shiny app to explore cell line transcriptional responses to anti-cancer drugs
Summary: The NCI Transcriptional Pharmacodynamics Workbench (NCI TPW) is an extensive compilation of directly measured transcriptional responses to anti-cancer agents across the well-characterized NCI-60 cancer cell lines. The NCI TPW data are publicly available through a web interface that allows limited user interaction with the data. We developed ‘TPWshiny’ as a standalone, easy to install, R application to facilitate more interactive data exploration.With no programming skills required, TPWshiny provides an intuitive and comprehensive graphical interface to help researchers understand the response of tumor cell lines to 15 therapeutic agents. The data are presented in interactive scatter plots, heatmaps, time series and Venn diagrams. Data can be queried by drug concentration, time point, gene and tissue type. Researchers can download the data for further analysis.Availability and implementation: Users can download the ready-to-use, self-extracting package for Windows or macOS, and R source code from the project website (https://brb.nci.nih.gov/TPWshiny/). TPWshiny documentation and additional information can be found on the project website.
- 23 June 2021
- Published by Springer Nature
- p. 49-62
Application of Systems Biology Approaches for Host-Fungal Interaction in Animals
- 23 June 2021
- Published by Springer Nature
- p. 49-62
Application of Systems Biology Approaches for Host-Fungal Interaction in Animals